Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 36.25
Bid: 36.00
Ask: 36.50
Change: 0.00 (0.00%)
Spread: 0.50 (1.389%)
Open: 36.25
High: 36.25
Low: 36.25
Prev. Close: 36.25
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Framework Distribution Agreement for India

26 Sep 2019 07:00

RNS Number : 7058N
Creo Medical Group PLC
26 September 2019
 

Creo Medical Group plc

("Creo" or the "Company")

 

Framework Distribution Agreement for India

Indian doctors and nurses trained on Speedboat following signing

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces it has entered into a Distribution Partner Framework Agreement (the "Agreement") with MEDITEK SYSTEMS ("Meditek"), to provide clinical training and market seeding across the Indian market for Creo's CROMA Advance Energy platform and suite of products, including the Speedboat device, ahead of their official launch.

 

Meditek will collaborate with Creo to advance the roll out of Creo's Clinical Education Programme across the Indian market, training key clinicians in the use of Speedboat and the CROMA platform with the aim of ensuring quality control and best patient outcomes. Creo's Clinical Education Programme ensures that distributor trainers, having been carefully mentored, can then deliver in-country training for clinicians at a consistently high standard.

 

In addition, doctors and nurses from six key healthcare institutions in India have already completed training as part of Creo's Clinical Education Programme ahead of the mentoring phase of the programme with initial cases taking place in India over the coming weeks.

 

Meditek will continue to operate the Clinical Education Programme in India and will commence seeding these markets with Creo's products, with the ultimate objective of entering into a formal long-term distribution agreement once the seeding phase has completed. The Agreement requires Meditek to purchase a minimum quantity of CROMA advance energy platforms and Speedboat products during the initial period.

 

About Speedboat

The Company's Speedboat device is the first in a range of GI devices to be cleared for use with the CROMA advanced energy platform, which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation. Speedboat enables the removal of lesions from the colon using an endoscope, whilst patients are under sedation and with regular procedure times of under one hour. Patients can be discharged on the same day for routine follow-up and monitoring, without recourse to lengthy laparoscopic surgery which requires hospitalised recovery over a number of days.

 

Craig Gulliford, Chief Executive Officer of Creo, commented: "We are delighted to begin working with Meditek to introduce our innovative product range to the Indian market, one of the fastest growing healthcare markets in the world which is also rapidly gaining recognition for pioneering clinical practice. We will continue to widen the reach of our Clinical Education Programme to ensure the highest standards are applied to the safe and effective adoption of our portfolio of products for surgical endoscopy."

 

Creo Medical Group plc

investors.creomedical.com

Richard Rees (CFO)

+44 (0)1291 606 005

 

 

Cenkos Securities

+44 (0)20 7397 8900

Stephen Keys / Cameron MacRitchie

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893

Lianne Cawthorne

Mob: +44 (0)7515 909 238

 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiofrequency energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar RF for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

 

The Company's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes that its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

 

For more information about Creo Medical please see our website, investors.creomedical.com

 

About Meditek Systems

Meditek Systems was formed in 1997 and is headquartered in New Delhi, India. Meditek aims to provide the latest available products to the medical industry in India and is one of India's fastest growing marketing & distribution houses dealing with several Multinational corporations which are industry experts and leaders in device manufacturing for Cardiology, Gastroenterology, Respiratory and Radiology. https://www.mediteksystems.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLAMMTMBJTTJL
Date   Source Headline
25th Apr 20247:00 amRNSNotice of Results
24th Apr 20247:00 amRNSNHS Speedboat data demonstrates savings
20th Mar 20244:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSWelsh Labour Leader visits Creo’s facilities
13th Mar 20243:05 pmRNSHolding(s) in Company
11th Mar 20242:00 pmRNSLTIP Awards
6th Mar 20244:35 pmRNSHolding(s) in Company
1st Mar 20247:00 amRNSMicrowave Lung Ablation Update
7th Feb 20249:12 amRNSTrading Update - Replacement
7th Feb 20247:00 amRNSTrading Update
5th Feb 20247:00 amRNSStrategic Collaboration with Khalifa University
31st Jan 20247:00 amRNSSpeedboat® UltraSlim roll-out reaches Asia Pacific
22nd Jan 20247:00 amRNSAward of Shares under Share Incentive Plan
10th Jan 20247:00 amRNSFirst use of Speedboat® UltraSlim in Latin America
15th Dec 20237:00 amRNSFirst use of Speedboat® UltraSlim in the USA
13th Dec 20237:00 amRNSFirst European Speedboat® UltraSlim procedure
7th Nov 20237:00 amRNSCapital Markets Day
1st Nov 20237:00 amRNSSpeedboat® UltraSlim: US FDA Clearance
25th Oct 20237:00 amRNSSB UltraSlim: EU launch accelerated by 18 months
16th Oct 202310:16 amRNSChange of Nominated Adviser and Joint Broker
12th Oct 20237:00 amRNSInvestor Presentation
12th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSNotice of Results
16th Aug 20237:00 amRNSRoyal Oldham SSD service update
3rd Aug 20237:00 amRNSHalf Year Trading Update
28th Jul 20237:00 amRNSTotal Voting Rights
24th Jul 202310:40 amRNSAward of Shares under Share Incentive Plan
6th Jul 202311:33 amRNSIssue of Equity and TVR
27th Jun 20231:15 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement & Directorate Succession Planning
26th Jun 20237:00 amRNSFirst upper GI Speedboat procedure in Europe
22nd Jun 20237:00 amRNSAppointment of Marco Scarci
19th Jun 20237:00 amRNSSpeedboat Inject upper GI clearance in Europe
1st Jun 20237:00 amRNSSpeedboat™ Inject selected by NICE for assessment
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFirst in-human milestone for MicroBlate™ Flex
17th May 20237:00 amRNSRoyal Oldham Hospital Agreement
15th May 20237:00 amRNSAttendance at Digestive Disease Week
26th Apr 20237:00 amRNSFinal Results
14th Apr 20237:00 amRNSAlbyn Medical earn out update
31st Mar 202310:45 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSMicroBlate™ Flex clinical study
13th Mar 20236:13 pmRNSDirector/PDMR and PCA Share Dealings
13th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 202310:25 amRNSResult of GM
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn
17th Feb 20232:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.